Skip to content

Clinical study on effect of different duration of moxibustion on quality of life in patients with rheumatoid arthritis of cold-dampness obstructin type

Clinical study on effect of different duration of moxibustion on quality of life in patients with rheumatoid arthritis of cold-dampness obstructin type

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039128
Enrollment
Unknown
Registered
2020-10-17
Start date
2019-10-01
Completion date
Unknown
Last updated
2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis of cold-dampness obstructin type

Interventions

Sponsors

Hubei Provincial Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients met the diagnostic criteria of rheumatoid arthritis of cold dampness obstruction type; 2. Patients aged 18-60 years; 3. Patients with definite joint pain; 4. Those who have not used glucocorticoids or muscle relaxants in the past week, or those who have taken the above drugs in a short period (3-5 days) and stopped using them for more than 7 days; 5. Patients who have not received acupuncture and moxibustion treatment within one week; 6. Those patients who had informed consent to this study and voluntarily participated in the follow-up. Note: patients who meet the above 6 items can be included in this study.

Exclusion criteria

Exclusion criteria: 1. Advanced patients with severe joint deformity, grade IV joint function, ankylosing spondylitis, psoriatic arthritis, gouty arthritis and systemic lupus erythematosus; 2. Patients with blood, liver, cardiovascular disease, diabetes or other severe joint symptoms, such as joint swelling, hot pain, local flush on body surface, body surface damage, burning, etc.; 3. Patients with respiratory diseases and allergic to moxibustion and ginger; 4. Pregnant or lactating women; 5. The patients with mental illness can not cooperate with the treatment; 6. Patients with previous history of tumor and tuberculosis. Note: any one of the above six items can not be included in this study.

Design outcomes

Primary

MeasureTime frame
erythrocyte sedimentation rate;C-reactive protein;Quality of life;Symptom and sign rating scale;Effect evaluation;

Secondary

MeasureTime frame
blood routine;urine routine;

Countries

China

Contacts

Public ContactWan Changxiu

Hubei University of Chinese Medicine

919258768@qq.com+86 13995659518

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026